Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

If You Own Simulations Plus (SLP) Stock, Should You Sell It Now?

Lakewood Capital Management recently released its Q2 2020 Investor Letter, a copy of which you can download here. In the letter, among other things, the fund reported a net profit of 10.7% for Q2 2020. You should check out Lakewood Capital’s top 5 stock picks for investors to buy right now, which could be the biggest winners of the stock market crash.

In the said letter, Lakewood Capital highlighted a few stocks and Simulations Plus Inc (NASDAQ:SLP) is one of them. Simulations Plus Inc (NASDAQ:SLP) is a software company. Year-to-date, Simulations Plus Inc (NASDAQ:SLP) stock gained 125.5% and on August 3rd it had a closing price of $72.09. Here is what Lakewood Capital said:

“In recent months, the valuations for hyper-growth software companies have surged to extraordinary heights. Amidst all this excitement, we have seen some lower-quality companies that have been reporting attractive headline growth mistakenly pulled along for the ride, creating a number of interesting short opportunities. The fund is short Simulations Plus, formerly a small-capitalization software company with limited sell-side coverage. Far from a hot start-up, Simulations Plus is actually a fairly mature 25 year-old company with the majority of its growth coming from a lower-margin consulting business and acquisitions. After getting caught up in the recent software rally, Simulations Plus was added to the S&P SmallCap 600 Index in June, sending its stock price up over 50% in a matter of weeks. Consequently, the company now trades at nearly 30x revenue with just mid-teens organic revenue growth of questionable quality.

Simulations Plus sells license software for pharmaceutical research and development, and its core product, GastroPlus, simulates the mechanics and interactions of drug compounds. While GastroPlus is by all measures a quality, leading product, its addressable market is fairly limited, with revenues growing to just around $20 million since its launch in the mid-90s. Over the past several years, the company began a series of acquisitions which meaningfully accelerated reported growth. In 2014, Simulations Plus acquired a company called Cognigen for $7 million at a valuation multiple of roughly 1x revenue, expanding into consulting services for pharmaceutical companies. Since then, the company acquired two smaller software and consulting competitors, both at low-single digit revenue multiples. In total, Simulations Plus has spent just over $30 million to acquire businesses accounting for nearly half of current revenue, in stark contrast to the company’s current market valuation of $1.2 billion.

The company’s consulting business now accounts for nearly half of its $40 million in annual revenues. In the most recent quarter, consulting revenues grew over 30% while software revenues grew 7% organically. While the consulting business has proven to be a success at the top line, results at the bottom line have been more mixed with margins steadily compressing over the last few years as the company has been forced to add headcount to support growth. Despite adding $10 million of company-wide revenue over the last two years, reported pre-tax income increased by only $2 million (even with an acquisition). While many high-growth companies show limited operating leverage as they aggressively invest in new products, this does not appear to be the case at Simulations Plus with annual R&D expense of just $2.5 million.

While we understand the basis for early-stage, subscription software companies to be valued off of revenue multiples, we believe it is more appropriate for Simulations Plus to be valued off of its earnings levels since, after all, Simulations Plus is not early stage, subscription-based or even entirely software. With the index addition now complete, we expect the stock to converge back toward its historical average multiple of 30x forward earnings (instead of 30x revenue). We forecast that the company will generate just over $0.60 of EPS next fiscal year, and at a multiple of 30x earnings (in line with its historical average despite the higher mix of the lower-quality consulting business today), the stock would trade at $18 per share, representing approximately 70% downside.”

Office Laptop Working Websurfing pexels

Pixabay/Public Domain

In Q1 2020, the number of bullish hedge fund positions on Simulations Plus Inc (NASDAQ:SLP)  stock decreased by about 17% from the previous quarter (see the chart here), so a number of other hedge fund managers seem to agree with Simulations Plus’s downside potential. Our calculations showed that Simulations Plus Inc (NASDAQ:SLP)  isn’t ranked among the 30 most popular stocks among hedge funds.

The top 10 stocks among hedge funds returned 185% since the end of 2014 and outperformed the S&P 500 Index ETFs by more than 109 percentage points. We know it sounds unbelievable. You have been dismissing our articles about top hedge fund stocks mostly because you were fed biased information by other media outlets about hedge funds’ poor performance. You could have doubled the size of your nest egg by investing in the top hedge fund stocks instead of dumb S&P 500 ETFs. Below you can watch our video about the top 5 hedge fund stocks right now. All of these stocks had positive returns in 2020.

Video: Top 5 Stocks Among Hedge Funds

At Insider Monkey we scour multiple sources to uncover the next great investment idea. Cannabis stocks are roaring back in 2020, so we are checking out this under-the-radar stock. We go through lists like the 10 most profitable companies in the world to pick the best large-cap stocks to buy. Even though we recommend positions in only a tiny fraction of the companies we analyze, we check out as many stocks as we can. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. If you want to find out the best healthcare stock to buy right now, you can watch our latest hedge fund manager interview here. You can subscribe to our free enewsletter below to receive our stories in your inbox:

Disclosure: None. This article is originally published at Insider Monkey.